Lilly Ventures,  
礼来公司的第一支投资基金—礼来风险基金（Lilly Ventures, ）设立于2001年，专注于北美和欧洲地区的投资。
礼来亚洲基金（Lilly Asia Ventures）设立于2008年，专注于亚洲尤其是中国地区的投资.我们也是目前中国唯一的一支由跨国制药公司设立的投资基金。通过礼来公司这根纽带，我们为被投资公司带来巨大的战略资源并提供出色的增值服务。

 




Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company. Our investment philosophy drives us to seek great companies with compelling life science innovations. We partner actively with the management teams of our portfolio companies to realize the potential of their technologies. Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success. Lilly Ventures currently has $200 million under management with a focus on the North American and European regions.

Investment Focus
Biotechnology: targeting investments in biotechnology companies that leverage proprietary drug discovery or development technologies to build a multi-product pipeline.

Medical Technology: targeting investments in companies focusing on the convergence of devices with pharmaceuticals or diagnostics.

Value Added Resources
ACCESS TO INDUSTRY KNOWLEDGE AND CONTACTS

Through our relationship with Eli Lilly and Company, Lilly Ventures provides our portfolio companies with access to the collective knowledge and contact base generated by Lilly's world-class scientists, experienced clinical investigators and respected sales and marketing professionals

PRODUCT INSIGHTS
Our relationship with Eli Lilly and Company greatly enhances our ability to evaluate new technologies and therapies from a customer or prospective partner perspective.

STRATEGIC RELATIONSHIPS
Our collaborations with industry experts, the venture capital industry and investment banks give us a global network of contacts to assist portfolio companies with various aspects of growing their business.